Cantor Fitzgerald, L. P. Aurinia Pharmaceuticals Inc. Transaction History

Cantor Fitzgerald, L. P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $449,995 - $849,788	-91,277 Reduced 62.82%	54,033 $270,000
Q4 2023 Feb 14, 2024	BUY	$7.13 - $9.49 $510,893 - $679,996	71,654 Added 97.28%	145,310 $1.31 Million
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $27,569 - $35,970	-3,077 Reduced 4.01%	73,656 $712,000
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $147,193 - $279,270	24,780 Added 47.7%	76,733 $840,000
Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $409,725 - $811,476	-99,690 Reduced 65.74%	51,953 $224,000
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $103,762 - $193,036	-15,580 Reduced 9.32%	151,643 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $1.5 Million - $2.14 Million	167,223 New	167,223 $1.68 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.